TY - JOUR
T1 - Correction
T2 - Tuberculosis (TB) Aftermath: study protocol for a hybrid type I effectiveness-implementation non-inferiority randomized trial in India comparing two active case finding (ACF) strategies among individuals treated for TB and their household contacts (Trials, (2022), 23, (635), 10.1186/s13063-022-06503-6)
AU - the TB Aftermath study team
AU - Cox, Samyra R.
AU - Kadam, Abhay
AU - Atre, Sachin
AU - Gupte, Akshay N.
AU - Sohn, Hojoon
AU - Gupte, Nikhil
AU - Sawant, Trupti
AU - Mhadeshwar, Vishal
AU - Thompson, Ryan
AU - Kendall, Emily
AU - Hofmann, Christopher
AU - Suryavanshi, Nishi
AU - Kerrigan, Deanna
AU - Tripathy, Srikanth
AU - Kakrani, Arjunlal
AU - Barthwal, Madhusudan S.
AU - Mave, Vidya
AU - Golub, Jonathan E.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Following publication of the original article [1], we have been notified that sputum collection has been done at the TU instead of at home, as originally stated in the paper. This change was made due to logistical constraints. The Interventions and Data collection and management sections have been modified to reflect this. In the Sample size section, second paragraph, the phrase “Assuming a rate of 12 TB cases per 100 person-years (…) we are powered at 80% to determine that the TACF arm is non- inferior to the HACF arm with a non-inferiority interval of 3 per 100 person-years and a sample size of 1076 index patients and two HHCs per index patient (n = 2152)” was also modified into “Assuming a rate of 12 TB cases per 100 person-years (…) we are powered at 90% to determine that the TACF arm is non- inferior to the HACF arm with a non-inferiority interval of 1.7 per 100 person-years and a sample size of 1076 index patients and two HHCs per index patient (n = 2152)” (changes marked in bold). 3 was also changed into 1.7 into the Statistical Methods section (“the upper bound of this estimate is less than 1.7 per 100 person-years”). 3 per 100 person-years applied to recurrent cases only. The non-inferiority margin for the primary outcome which includes both new and recurrent cases is 1.7 per 100 person-years. The author contribution section was also modified to include the statement: “SA and TS resigned from the study and were not involved in the discussion related to the manuscript correction.” The original article has been corrected.
AB - Following publication of the original article [1], we have been notified that sputum collection has been done at the TU instead of at home, as originally stated in the paper. This change was made due to logistical constraints. The Interventions and Data collection and management sections have been modified to reflect this. In the Sample size section, second paragraph, the phrase “Assuming a rate of 12 TB cases per 100 person-years (…) we are powered at 80% to determine that the TACF arm is non- inferior to the HACF arm with a non-inferiority interval of 3 per 100 person-years and a sample size of 1076 index patients and two HHCs per index patient (n = 2152)” was also modified into “Assuming a rate of 12 TB cases per 100 person-years (…) we are powered at 90% to determine that the TACF arm is non- inferior to the HACF arm with a non-inferiority interval of 1.7 per 100 person-years and a sample size of 1076 index patients and two HHCs per index patient (n = 2152)” (changes marked in bold). 3 was also changed into 1.7 into the Statistical Methods section (“the upper bound of this estimate is less than 1.7 per 100 person-years”). 3 per 100 person-years applied to recurrent cases only. The non-inferiority margin for the primary outcome which includes both new and recurrent cases is 1.7 per 100 person-years. The author contribution section was also modified to include the statement: “SA and TS resigned from the study and were not involved in the discussion related to the manuscript correction.” The original article has been corrected.
UR - http://www.scopus.com/inward/record.url?scp=85187211610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85187211610&partnerID=8YFLogxK
U2 - 10.1186/s13063-024-07984-3
DO - 10.1186/s13063-024-07984-3
M3 - Comment/debate
C2 - 38468342
AN - SCOPUS:85187211610
SN - 1745-6215
VL - 25
JO - Trials
JF - Trials
IS - 1
M1 - 178
ER -